NASDAQ:BLRX
BioLineRx Ltd. Stock News
$1.12
+0.0100 (+0.90%)
At Close: Mar 28, 2024
BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update
07:00am, Wednesday, 26'th May 2021
TEL AVIV, Israel, May 26, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for
BioLineRx to Report First Quarter 2021 Results on May 26, 2021
07:00am, Thursday, 20'th May 2021
TEL AVIV, Israel, May 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its un
BLRX Stock: From $4.88 To $5.18 (6.15% Increase) Pre-Market Explanation
08:16am, Wednesday, 05'th May 2021
The stock price of BioLineRx (NASDAQ: BLRX) increased from $4.88 to $5.18 (up 6.15%) pre-market. This is why it happened.
Why Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving Today
01:45pm, Tuesday, 04'th May 2021
Cocrystal Pharma, Inc. (NASDAQ: COCP), ChemoCentryx, Inc. (NASDAQ: CCXI), Neuronetics, Inc. (NASDAQ: STIM) and BioLineRx Ltd. (NASDAQ: BLRX) are among the biggest health care movers Tuesday.
BioLineRx Stock Is Trading Higher As Motixafortide-G-CSF Combo Shows Promise In Transplant Setting For Multiple Myeloma Patients
08:19am, Tuesday, 04'th May 2021
BioLineRx (NASDAQ: BLRX) has announced positive top-line results from GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, combined with granulocyte colony-stimulating fact
BLRX Stock: From $3.19 To $5.07 (58.93% Increase) Pre-Market Explanation
07:55am, Tuesday, 04'th May 2021
The stock price of BioLineRx (NASDAQ: BLRX) increased from $3.19 to $5.07 (58.93% increase) pre-market. This is why it happened.
TEL AVIV, Israel, May 4, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive top-line result
Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week
01:22pm, Saturday, 24'th Apr 2021
5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | Penn
BioLineRx Announces Presentation at 2021 American Association for Cancer Research (AACR) Annual Meeting
07:14am, Thursday, 15'th Apr 2021
TEL AVIV, Israel, April 15, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company has p
BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2020 Results - Earnings Call Transcript
12:06pm, Tuesday, 23'rd Feb 2021
BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2020 Results - Earnings Call Transcript
BioLineRx: Investors Are About To Cash In On Motixafortide's Phase 3 Results
06:01pm, Wednesday, 27'th Jan 2021
BioLineRx: Investors Are About To Cash In On Motixafortide's Phase 3 Results
BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter
04:15pm, Friday, 22'nd Jan 2021
TEL AVIV, Israel, Jan. 22, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of its prev
BLRX Stock Price Falls Over 20% Pre-Market: Why It Happened
07:03am, Wednesday, 20'th Jan 2021
The stock price of BioLineRx (NASDAQ: BLRX) is trading over 20% lower pre-market today. This is why it happened.
BioLineRx Increases Previously Announced Bought Deal Offering to $30 Million
09:42pm, Tuesday, 19'th Jan 2021
TEL AVIV, Israel, Jan. 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that due to demand, the
BioLineRx Announces $10 Million Bought Deal Offering
04:55pm, Tuesday, 19'th Jan 2021
TEL AVIV, Israel, Jan. 19, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered int